Nurses at West Cancer Center in Memphis, Tennessee, developed a best nursing practice protocol for titration of fentanyl sublingual spray (FSS; Subsys) for breakthrough cancer pain. Studies show that ...
Fentanyl sublingual spray is safe for long-term use for cancer pain, according to a study reported in Monthly Prescribing Reference. In study results presented at the American Pain Society’s 31st ...
HONOLULU, HI—Fentanyl sublingual spray is generally safe and well tolerated for long-term use in opioid-tolerant patients with cancer for the treatment of breakthrough pain, study investigators at the ...
Please provide your email address to receive an email when new articles are posted on . Fentanyl sublingual spray was associated with improvements in a number of pain and adverse event categories in a ...
HONOLULU, HI—Fentanyl sublingual spray can be safely titrated to an effective dose in patients with breakthrough cancer pain, a study presented at the American Pain Society’s 31 st Annual Scientific ...
PHOENIX, AZ--(Marketwired - Oct 29, 2015) - Insys Therapeutics, Inc. (NASDAQ: INSY) ("Insys" or "the Company") today announced that the U.S. Food and Drug Administration ("FDA") has granted Fast Track ...
NSYS Therapeutics' SUBSYS™, which uses an Aptar Pharma Sublingual Unit-Dose Spray (UDS) device, has been launched in the USA for breakthrough cancer pain in patients with cancer who are 18 years of ...
Insys Therapeutics has launched Subsys fentanyl sublingual spray to manage recurring cancer pain, according to Pharmaceutical Business Review. The spray is available in 100mcg through 1600mcg doses ...
PHOENIX, AZ--(Marketwired - Oct 29, 2015) - Insys Therapeutics, Inc. (NASDAQ: INSY) ("Insys" or "the Company") today announced that the U.S. Food and Drug Administration ("FDA") has granted Fast Track ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results